


IN THE CLAIMS

1. (canceled).
2. (Previously presented) A compound of formula (I)



wherein:

R<sup>1</sup> is selected from:

- a) phenyl, which is optionally substituted by 1-3 groups each independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, CF<sub>3</sub>, halo, CN, NR<sup>7</sup>R<sup>8</sup>, SO<sub>2</sub>R<sup>6</sup> and OC<sub>1</sub>-C<sub>6</sub> alkyl, and
- b) Aromatic Heterocycle, wherein said Aromatic Heterocycle is selected from pyridyl, pyrazinyl, pyrimidinyl, quinoliny, quinoxaliny, isoxazolyl and pyrazolyl, each aromatic heterocycle optionally substituted by 1-3 groups each independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, SR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, NH<sub>2</sub>, CF<sub>3</sub>, halo, OH, OC<sub>1</sub>-C<sub>6</sub> alkyl, NR<sup>7</sup>R<sup>8</sup> wherein R<sup>8</sup> may be optionally substituted by NH<sub>2</sub>, phenyl or Heterocycle, and OPh wherein Ph may be optionally substituted by 1-3 groups each independently selected from halo and C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>2</sup> is selected from:

- a) phenyl, which is optionally substituted by methyl, fluoro, chloro, methoxy, CF<sub>3</sub> or SO<sub>2</sub>CH<sub>3</sub>,
- b) pyrazolyl, which is optionally substituted by methyl, and
- c) C(O)N(CH<sub>3</sub>)<sub>2</sub>;

R<sup>3</sup> is selected from:

- a) phenyl, said phenyl being optionally fused to Heterocycle and said phenyl or said fused phenyl being optionally substituted by 1-3 groups each independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, halo, CN and OC<sub>1</sub>-C<sub>6</sub> alkyl,
- b) R<sup>6</sup>,
- c) cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, which is optionally substituted by C<sub>1</sub>-C<sub>6</sub> alkyl; and
- d) Aromatic Heterocycle, wherein said Aromatic Heterocycle may be defined as a 5-6 membered aromatic heterocycle containing 1 or 2 nitrogen atoms, said ring optionally fused with a phenyl or a 3-8 membered cycloalkyl group.

R<sup>4</sup> is H;

R<sup>5</sup> is CONH<sub>2</sub>;

R<sup>6</sup> is methyl;

R<sup>7</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>8</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl;

or NR<sup>7</sup>R<sup>8</sup> forms a monocyclic saturated ring system containing between 3 and 7 ring atoms;

x is 1;

y is 0; and

z is 0 or 1

wherein:

Aromatic Heterocycle may be defined as a 5-6 membered aromatic heterocycle containing 1-4 heteroatoms each independently selected from N, O and S, said ring optionally fused with a phenyl or a 3-8 membered cycloalkyl group;

Heterocycle is a 5-8 membered saturated or partially saturated ring containing 1-3 heteroatoms each independently selected from N, O and S, said ring optionally fused with phenyl;

a tautomer thereof or a pharmaceutically acceptable salt, solvate or polymorph of said compound or tautomer.

3. (Currently amended) A compound according to claim 2 wherein R<sup>1</sup> is selected from:

- a) phenyl, which is optionally substituted by 1-3 groups each independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, CF<sub>3</sub>, halo, CN, NR<sup>7</sup>R<sup>8</sup>, SO<sub>2</sub>R<sup>6</sup> and OC<sub>1</sub>-C<sub>6</sub> alkyl, and
- b) Aromatic Heterocycle, wherein said Aromatic Heterocycle is selected from:
  - i) pyridyl, which is optionally substituted by 1-3 groups each independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, SO<sub>2</sub>R<sup>6</sup>, NH<sub>2</sub>, CF<sub>3</sub>, CN, halo, OH, OC<sub>1</sub>-C<sub>6</sub> alkyl, NR<sup>7</sup>R<sup>8</sup> wherein R<sup>8</sup> may be optionally substituted by NH<sub>2</sub>, phenyl or Heterocycle, and OPh wherein Ph may be optionally substituted by 1-3 groups each independently selected from halo and C<sub>1</sub>-C<sub>6</sub> alkyl;
  - ii) pyrimidinyl, which is optionally substituted by 1-3 groups each independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, SO<sub>2</sub>R<sup>6</sup>, NH<sub>2</sub>, CF<sub>3</sub>, CN, halo, OH, OC<sub>1</sub>-C<sub>6</sub> alkyl, NR<sup>7</sup>R<sup>8</sup> wherein R<sup>8</sup> may be optionally substituted by NH<sub>2</sub>, phenyl or Heterocycle, and OPh wherein Ph may be optionally substituted by 1-3 groups each independently selected from halo and C<sub>1</sub>-C<sub>6</sub> alkyl;
  - iii) pyrazinyl, which is optionally substituted by 1-3 groups each independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, NH<sub>2</sub>, SR<sup>6</sup> and halo;
  - iv) quinolinyl;
  - v) quinoxaliny, which is optionally substituted by OH;
  - vi) isoxazolyl, which is optionally substituted by 1-3 groups each independently selected from: C<sub>1</sub>-C<sub>6</sub> alkyl; and
  - vii) pyrazole;

~~R<sup>2</sup> is selected from:~~

- ~~a) phenyl, which is optionally substituted by methyl, halo, methoxy, CF<sub>3</sub> or SO<sub>2</sub>CH<sub>3</sub>;~~
- ~~b) cyclopropyl or 1- or 2-indanyl;~~
- ~~c) pyrazolyl, which is optionally substituted by methyl;~~
- ~~d) C(O)N(CH<sub>3</sub>)<sub>2</sub>, and~~
- ~~e) piperidinyl substituted by C(O)R<sup>6</sup>.~~

R<sup>3</sup> is selected from:

- a) phenyl, said phenyl being optionally fused to 1,4-dioxan and said phenyl or said fused phenyl being optionally substituted by 1-3 groups each independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, halo, CN and OC<sub>1</sub>-C<sub>6</sub> alkyl;
- b) R<sup>6</sup>,
- c) cyclopropyl, which is optionally substituted by C<sub>1</sub>-C<sub>6</sub> alkyl; and
- d) Aromatic Heterocycle, wherein said Aromatic Heterocycle is selected from pyrazolyl or pyridyl, both optionally substituted by C<sub>1</sub>-C<sub>6</sub> alkyl;

~~R<sup>5</sup> is CONH<sub>2</sub> or CH<sub>3</sub>; and~~

z is 0.

4. (Currently amended) A compound according to any one of claims 1 to 2 or 3 wherein R<sup>1</sup> is phenyl, 2- or 3-pyridyl or 2,4-pyrimidinyl, said moieties being optionally substituted by 1-3 groups each independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, halo, OC<sub>1</sub>-C<sub>6</sub> alkyl, CN, SO<sub>2</sub>R<sup>6</sup>, NHR<sub>7</sub>, NHCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub> and CF<sub>3</sub>;

5. (original) A compound according to claim 4 wherein R<sup>1</sup> is phenyl, 2- or 3-pyridyl or 2,4-pyrimidinyl, said moieties being optionally substituted by 1-3 groups each independently selected from methyl, fluoro, chloro, methoxy, ethoxy, n-propoxy, CN, SO<sub>2</sub>CH<sub>3</sub>, NH<sub>2</sub>, NHCH<sub>3</sub>, NHCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, and CF<sub>3</sub>.

6. (canceled)

7. (previously presented) A compound according to claim 5 wherein R<sup>2</sup> is phenyl, *para*-fluorophenyl, *para*-chlorophenyl, *para*-methylphenyl, 2,5-dimethylphenyl, *o*-methylphenyl and *para*-methoxyphenyl.

8. (previously presented) A compound according to claim 7 wherein R<sup>3</sup> is selected from:

- a) phenyl, said phenyl being optionally fused to 1,4-dioxan and said phenyl or said fused phenyl being optionally substituted by 1-2 groups each independently selected from methyl, methoxy, ethoxy, fluoro, chloro and CN;

- b) isopropyl;
- c) cyclopropyl; and
- d) pyrazolyl and pyridyl, both optionally substituted by methyl.

9. (original) A compound according to claim 8 wherein R<sup>3</sup> is 3-methoxyphenyl or 1,4-benzodioxanyl.

10. (Cancelled).

11. (Previously presented) A compound according to claim 2 selected from:

2-Amino-*N*-[2-amino-1-(2-methylphenyl)-2-oxoethyl]-*N*-(4-chlorobenzyl)nicotinamide,

*N*-[2-Amino-1-(3-methoxyphenyl)-2-oxoethyl]-4-cyano-*N*-(4-methylbenzyl)benzamide,

*N*-[3-Amino-1-(3-methoxyphenyl)-3-oxopropyl]-4-methyl-*N*-(4-methylbenzyl)nicotinamide,

2-Amino-*N*-[(1*S*)-3-amino-3-oxo-1-phenylpropyl]-*N*-(4-methylbenzyl)nicotinamide,

5-Chloro-2-methylthio-*N*-[2-amino-1-{1,4-benzodioxan-6-yl}-2-oxoethyl]-*N*-(4-methylbenzyl)pyrimidine-4-carboxamide,

5-Chloro-2-amino-*N*-[2-amino-1-{1,4-benzodioxan-6-yl}-2-oxoethyl]-*N*-(4-methylbenzyl)pyrimidine-4-carboxamide, and

2-Amino-*N*-[carbamoyl-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-methyl]-4,6-dimethyl-*N*-(4-methyl-benzyl)-nicotinamide;

and tautomers thereof and pharmaceutically acceptable salts, solvates and polymorphs of said compound or tautomer.

12. (Previously presented) A pharmaceutical composition comprising a compound of claim 2, or pharmaceutically acceptable salts, solvates or polymorphs thereof, and a pharmaceutically acceptable diluent or carrier.

13. (previously canceled)

14. (Previously presented) A method of treatment of a disorder or condition where inhibition of Oxytocin is known, or can be shown, to produce a beneficial

effect, in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of claim 2.

15. (previously canceled)

16. (Previously presented) A method according to claim 14 wherein the disorder or condition is selected from sexual dysfunction (including premature ejaculation), preterm labour, complications in labour, appetite and feeding disorders, obesity, benign prostatic hyperplasia, premature birth, dysmenorrhoea, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic hypertension, ocular hypertension, obsessive compulsive disorder and neuropsychiatric disorders.

17. (previously presented) A method according to claim 16, wherein the disorder or condition is premature ejaculation.